Agios Pharmaceuticals, Inc., a biopharmaceutical company, is dedicated to drug discovery and development in the field of cellular metabolism and adjacent areas of biology. The company is headquartered in Cambridge, Massachusetts. Show more

88 SIDNEY STREET, CAMBRIDGE, MA, UNITED STATES, 02139, Cambridge, MA, 02139, USA

https://www.agios.com

BIOTECHNOLOGY

HEALTHCARE

Start AI Chat

Market Cap

1.983B

52 Wk Range

$22.24 - $46.00

Previous Close

$33.60

Open

$33.83

Volume

794,484

Day Range

$32.88 - $34.36

Enterprise Value

1.419B

Cash

99.65M

Avg Qtr Burn

-57.31M

Insider Ownership

1.07%

Institutional Own.

Qtr Updated

06/30/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
PYRUKYND (Mitapivat) Details Sickle cell disease, Anemia	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tibsovo (Ivosidenib) (IDH1m inhibitor) Details AML (Acute Myeloid Leukemia)	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
PYRUKYND (Mitapivat) Details Beta thalessemia	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VORANIGO (Vorasidenib) Details Glioma, Brain tumor	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
PYRUKYND (Mitapivat) Details Sickle cell disease, Anemia	PDUFA Approval decision	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
PYRUKYND (Mitapivat) Details Pyruvate Kinase Deficiency	NDA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Cevidoplenib (SYK Inhibitor) Details Immune Thrombocytopenia	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AG-236 Details Polycythemia vera	Phase 2/3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Pyrukynd/Mitapivat (TBA) (Pyruvate Kinase Activator) Details Hereditary Spherocytosis, Hereditary Xerocytosis, Congenital Dyserythropoietic Anemia Type Ii	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AG-181 Details Phenylketonuria	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tebapivat Details Sickle cell disease, Blood disorder	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tebapivat (AG-946) Details Myelodysplastic syndrome	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.